Overview of Etoricoxib/paracetamol

Quick Facts

Property	Description
Active Ingredients	Etoricoxib, Paracetamol (Acetaminophen)
Form	Oral Tablet
Pharmacological Class	Selective COX-2 Inhibitor, Non-opioid Analgesic
Common Use	Pain relief and inflammation reduction
Origin	Synthetic

Identity and Classification: What Type of Medicine is Etoricoxib/Paracetamol?

Etoricoxib/paracetamol is a synthetic combination medication provided for oral intake, typically in a tablet dosage form, that merges the actions of two distinct active pharmaceutical ingredients. This unique dual composition is classified pharmacologically as a combination of a highly selective Non-Steroidal Anti-Inflammatory Drug (NSAID) and a widely recognized non-opioid analgesic.

Specifically, Etoricoxib is a Cyclooxygenase-2 (COX-2) Inhibitor, a class characterized by its targeted action, while Paracetamol is categorized as a p-aminophenol derivative that also functions as an antipyretic. The combined nature dictates that this formulation is generally supplied as a prescription drug due to the specialized nature of the Etoricoxib component.

Core Composition and General Purpose

The medication’s core composition involves the direct pairing of Etoricoxib and Paracetamol to achieve a synergistic effect, intended to provide enhanced analgesic activity compared to the individual components alone. The primary general purpose of this combined preparation is to manage discomfort by addressing two fundamental aspects: pain perception and inflammatory signaling.

This dual mechanism is utilized for pain relief and associated inflammation reduction. The Etoricoxib component works to mitigate the localized production of prostaglandins that cause swelling, while the Paracetamol component contributes analgesic activity and antipyretic activity (fever reduction) primarily through central nervous system modulation. This formulation's differentiating factor lies in its ability to combine the selective anti-inflammatory properties of a Coxib with the established central pain relief of Paracetamol in one single preparation.

Therapeutic Uses of Etoricoxib/paracetamol

The primary role of this medication is to provide supportive assistance for symptom management in situations involving heightened discomfort, inflammation, and pain. The therapeutic scope typically covers conditions presenting with both acute episodes and recurrent inflammatory disorders.

This combination is commonly used to help with the symptomatic relief of pain, stiffness, and swelling associated with chronic conditions like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis. It is also applied when short-term symptomatic support is needed for episodes such as Acute Gouty Arthritis and pain following dental surgery.

The overall benefit focuses on easing the physical manifestations of distress: “The medication supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms are more noticeable.”

It is relevant in clinical settings that involve acute or unstable symptom patterns, contributing to easing the overall symptom load during periods when pain becomes more noticeable.

Quick Fact: Relief for Pain and Inflammation
Clinical Scenarios	Chronic joint disorders, acute gout flares, post-operative dental discomfort.
Symptom Focus	Pain, inflammation, stiffness, swelling, and fever.
Supportive Benefit Focus	Provides supportive relief that may assist with maintaining functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Etoricoxib/Paracetamol? (Official Regulatory Information)

The official eligibility for Etoricoxib/Paracetamol is defined by age, reproductive status, and the absence of specific, severe pre-existing conditions, as outlined in governmental regulatory documents.

Populations for Whom Use is Contraindicated

The medicine is strictly contraindicated and must not be used by several populations:

Age and Reproductive Status: Individuals under 16 years of age, and women who are pregnant or breastfeeding.
Hypersensitivity: Patients with known allergy to Etoricoxib, Paracetamol, or other NSAIDs (including those who react with bronchospasm or severe allergic symptoms to aspirin).
Cardiovascular Disease: Patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, Congestive Heart Failure (NYHA Class II-IV), or uncontrolled hypertension (persistently above 140/90 mmHg).
Gastrointestinal and Organ Function: Patients with active peptic ulceration, active GI bleeding, Inflammatory Bowel Disease, severe hepatic dysfunction (Child-Pugh score ge 10), or severe renal impairment (creatinine clearance < 30 ml/min).

Eligibility and Restrictions

Approved Population: Use is allowed for adults and adolescents ge 16 years of age.
Conditional Use: Patients with moderate hepatic dysfunction (Child-Pugh 7–9) face a restriction: a specific low daily dose must not be exceeded. Use in women attempting to conceive is not recommended. Patients with significant cardiovascular risk factors require a careful assessment before use.

What should I know about interactions with other medicines?

️ Interactions with other medicines and products

It is essential to inform your doctor or pharmacist about all prescription and non-prescription medicines, herbal products, and supplements you are taking, as Etoricoxib/paracetamol can interact with several other substances. These interactions can affect how the combination medicine works or increase the risk of side effects.

Increased Risk of Bleeding or Stomach Issues

Caution is required when taking Etoricoxib/paracetamol alongside medicines that increase the risk of bleeding or stomach ulcers. This includes anticoagulants (e.g., warfarin), low-dose aspirin for cardiovascular protection, and other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors. Concurrent use is generally not recommended.

Effects on Drug Levels and Efficacy

Etoricoxib/paracetamol can affect the levels and effects of other drugs. Particular monitoring is needed if you are taking:

Ciclosporin or tacrolimus (used after organ transplants or for autoimmune diseases) - may increase the risk of kidney problems.
Lithium (for certain types of depression) - its blood level may be increased.
Methotrexate (for rheumatoid arthritis and psoriasis) - its toxicity may be increased.
Diuretics and certain medicines for high blood pressure (e.g., ACE inhibitors, Angiotensin II Receptor Blockers).

Paracetamol absorption may be affected by drugs such as cholestyramine (to lower cholesterol) or metoclopramide (to treat nausea). Discuss all current treatments to ensure safe co-administration.

Mechanism of Action

Selective Cyclooxygenase-2 Inhibition

Etoricoxib acts within domains involving enzyme-mediated signaling by selectively inhibiting the Cyclooxygenase-2 (COX-2) enzyme. This action modifies early molecular steps that shape systemic physiological outcomes by suppressing the biosynthesis of pro-inflammatory prostaglandins from arachidonic acid at sites of tissue damage. This specific mechanism results in reduced concentration of inflammatory mediators, leading to predictable physiological adjustments influencing the local signaling cascade governed by prostanoids.

Central Pain Pathway Modulation

Paracetamol engages mechanisms that regulate overactive or dysregulated processes primarily within the central nervous system (CNS). While its exact mechanism is complex, it is thought to modulate central pain pathways by affecting mechanisms involving the inhibition of COX enzymes (predominantly COX-3 or central COX-2) and/or influencing serotonergic, opioid, or cannabinoid systems. This action initiates or suppresses signaling sequences involved in the transmission of nociceptive signals, ultimately modifying the activity of pathways involved in the perception of pain.

Dosage and Administration Information

The combination product Etoricoxib/paracetamol is administered orally in a once-daily regimen, a pattern dictated by the Etoricoxib component's pharmacological profile. The official dosing is determined by the specific condition being addressed, always requiring the lowest effective daily dose for the shortest duration possible. Tablets should be swallowed whole.

Official Usage Patterns

Instruction Domain	Official Guidance
Route and Frequency	Oral administration, once daily schedule.
Timing in Relation to Meals	May be taken with or without food. Administration without food may lead to a faster onset of effect.
Acute Course Duration	Limited to a maximum of 8 days for acute gouty arthritis and 3 days for postoperative dental pain.
Dosing for Chronic Conditions	Osteoarthritis (OA): 30 mg to max 60 mg once daily. Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS): 60 mg to max 90 mg once daily.

Population-Specific Adjustments

Population	Dosing Rule (Etoricoxib Component Max)
Older Adults (≥ 65)	No dosage adjustment is necessary.
Mild Hepatic Impairment (Child-Pugh 5–6)	Dose must not exceed 60 mg once daily.
Moderate Hepatic Impairment (Child-Pugh 7–9)	Dose must not exceed 30 mg once daily.

If a dose is missed, it is advised to continue the usual dose the following day; a double dose must never be taken to compensate for the missed administration. The overall protocol structures usage by mandating condition-specific doses and controlling the duration of administration, particularly for acute episodes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Etoricoxib/Paracetamol

The available research provides context for how Etoricoxib-containing regimens was studied, focusing on measured changes in symptom patterns and physical function in studied populations. The following summary reflects the structures and reported patterns of the clinical evidence, in line with regulatory and scientific assessments.

Evidence for Use in Chronic Joint Conditions

Research exploring outcomes related to physical discomfort and daily functioning in Osteoarthritis (OA)

Short-term and intermediate-term Randomized Controlled Trials (RCTs) was observed in research exploring the regimen for Osteoarthritis. The research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. Findings describe patterns observed in the studies where patient-reported outcomes describing perceived discomfort evolved in the observed populations. However, the evidence provides limited insight into very long-term (multi-year) patient outcomes across the entire study population, as there is limited information for long-term outcomes for the full duration.

Research exploring outcomes related to systemic imbalance in Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS)

The evidence base for Rheumatoid Arthritis and Ankylosing Spondylitis research examined both short-term RCTs and longer longitudinal trials. The research explored outcomes linked to inflammatory or irritative states and outcomes related to systemic or functional imbalance. Studies monitored changes in clinical measurements, such as tender and swollen joint counts and overall disease activity scores. Regulatory summaries have noted a need for further clinical studies to investigate the long-term effects and consistency of findings for AS, as the available evidence for that extended duration may be limited.

Evidence for Use in Acute Pain Episodes

Research exploring outcomes related to episodic or acute changes in Acute Gouty Arthritis

The research in this area was conducted during periods of increased symptom activity, utilizing short-term, active-comparator controlled clinical trials. Reported findings describe patterns related to outcomes capturing phases of heightened symptom activity and outcomes linked to inflammatory or irritative states. The key limitation here is that follow-up durations were limited; the evidence is strictly short-term, focusing on the acute episode (e.g., trials of up to 8 days).

Research exploring outcomes related to perceived discomfort Following Dental Surgery

Evidence for acute pain following surgery was evaluated in settings with varying symptom burdens, primarily using single-dose Randomized Controlled Trials (RCTs). Research explored outcomes capturing phases of heightened symptom activity, such as total measured change in discomfort over a few hours and the time until patients requested additional measured pain relief. The follow-up durations were limited to the immediate period, typically within 72 hours of a single dose.

What is Still Uncertain About the Research for Etoricoxib/Paracetamol

The research data show patterns related to limitations in several key areas. Official regulatory bodies have indicated that further research is ongoing to fully establish long-term outcomes for chronic conditions. The results apply only to the populations studied, and data for certain groups remain insufficient to fully characterize potential patterns observed in research contexts involving fluctuating or unstable symptoms. This highlights areas where the evidence contributes to the broader evidence landscape but where questions remain.

Frequently Asked Questions (FAQ)

Common questions about Etoricoxib/paracetamol (FAQ)

Q: Does taking the medicine with food affect how quickly it starts working?

A: According to the official product information, taking the medicine without food may lead to a faster onset of effect. However, studies indicate that the overall amount of medication absorbed does not change significantly based on administration with or without food.

Q: What is the official guidance on consuming alcohol while taking Etoricoxib/paracetamol?

A: Regulatory documents state that avoiding the consumption of alcohol is advised because it may contribute to increased drowsiness and can also increase the potential risk of stomach bleeding.

Q: What is the main difference between Etoricoxib and other older non-steroidal anti-inflammatory drugs (NSAIDs)?

A: Etoricoxib is officially described as an oral, selective cyclo-oxygenase-2 (COX-2) inhibitor. This means it works by targeting the COX-2 enzyme, which is mainly responsible for pain and inflammation, in contrast to older NSAIDs that typically inhibit both COX-1 and COX-2 enzymes.

Q: Does Etoricoxib/paracetamol carry a warning about affecting the ability to drive or operate machinery?

A: Official safety information indicates that dizziness and sleepiness have been reported as potential side effects. If these effects occur, activities requiring mental alertness, such as driving or operating machinery, should be avoided.

Q: Are there any reports of this medicine causing sleep disturbances or changes in mood?

A: Official documentation lists insomnia (difficulty sleeping) as an uncommon undesirable effect. Additionally, mood-related effects, including reports of anxiety, depression, and confusion, are listed as uncommon or rare effects associated with the Etoricoxib component.

Q: Can Etoricoxib/paracetamol mask symptoms of an infection, like fever?

A: Yes, the official warnings state that the Etoricoxib component of the drug can mask fever and other signs of local inflammation. This effect is important to be aware of, as fever and inflammation are common indicators of an underlying infection.

Q: Are there any special precautions for people with diabetes taking this medicine?

A: Regulatory warnings indicate that individuals with pre-existing conditions like diabetes are among those with cardiovascular risk factors. These individuals, like others with cardiovascular risk factors, are noted in regulatory information as requiring careful assessment before use.

Q: Does Etoricoxib/paracetamol have an effect on cholesterol levels?

A: Official information lists individuals with pre-existing high cholesterol among those with cardiovascular risk factors. Regulatory documents note that these individuals, like others with cardiovascular risk factors, should have a careful assessment before initiating use of the medicine.

Q: What official information is available about Etoricoxib's impact on fertility?

A: Regulatory documents state that Etoricoxib, like other medicines that inhibit prostaglandin synthesis, is not recommended for women who are attempting to conceive. This is based on the drug’s mechanism of action, which may have the potential to affect female fertility.

Q: Does Etoricoxib/paracetamol affect the effectiveness of oral contraceptive pills?

A: Official interaction information notes that Etoricoxib may increase the incidence of adverse events associated with taking oral contraceptives. Information about this and all current treatments is important for safe co-administration.

Q: Why might a doctor prescribe this combination instead of separate Etoricoxib and Paracetamol tablets?

A: Official documents recognize that the combination product is associated with a synergistic effect, which is described as providing enhanced analgesic activity compared to the individual components alone. This combination aims to provide robust management of pain and inflammation.

Q: Is Etoricoxib combined with paracetamol instead of being sold alone?

A: Yes, Etoricoxib is available both in this combination product with paracetamol and as a single-agent product containing only Etoricoxib in various strengths. This allows prescribers to determine the formulation that best meets the patient's specific needs.

Q: Can Etoricoxib/paracetamol cause gastrointestinal bleeding without a prior history of ulcers?

A: Official safety profiles document that major gastrointestinal complications, including ulceration, bleeding, or perforation, have been reported with this class of medication. The risk of these events may increase depending on the dose used and the duration of therapy.

Q: What should patients know about the potential for allergic reactions to this combination?

A: Rare but severe hypersensitivity reactions (like anaphylaxis, which involves a rapid, whole-body allergic response) have been reported in official documents. Patients must be aware of the potential for these reactions to occur.

Q: How does this combination drug address pain associated with conditions like rheumatoid arthritis?

A: The pain associated with chronic conditions may be managed through the drug’s dual mechanism of action. Etoricoxib (a selective COX-2 inhibitor) targets the underlying inflammation and swelling, while Paracetamol (a central analgesic) helps modulate the perception of pain.

How should Etoricoxib/paracetamol be stored and disposed of?

Official Storage and Disposal Requirements

Etoricoxib/paracetamol tablets must be stored and disposed of according to specific regulatory guidelines to ensure product stability and safety. This medication must be stored at a temperature below 30°C (86°F), and it is mandatory to keep the tablets in the original blister pack or container to protect them from moisture and heat. Like all medicines, the product must be kept out of the sight and reach of children to prevent accidental exposure.

Storage Focus	Requirement (Official Labeling)
Temperature	Store below 30 C
Protection	Keep in original container; protect from moisture
Safety	Keep out of the sight and reach of children

For disposal, unused or expired medication must not be thrown away via household trash or wastewater. Instead, the product should be returned to a pharmacy or disposed of according to local pharmaceutical waste requirements.

Etoricoxib/paracetamol